SwanBio Therapeutics
Manufacturing · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
150 Monument Rd, Bala Cynwyd, Pennsylvan...Phone Number
(610) 557-0600Website
www.swanbiotx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About SwanBio Therapeutics
SwanBio Therapeutics, a gene therapy company developing leading-edge medicines to deliver dramatic clinical efficacy for the treatment of adrenomyeloneuropathy (AMN) and other neurological diseases, today announced the appointment of Steven Zelenkofske, D.O., M.S. as chief medical officer (CMO). Dr. Zelenkofske brings more than 20 years of experience to the SwanBio Therapeutics team, most recently serving as the CMO at Achillion Pharmaceuticals, a clinical stage company focused on complement inhibitors, and at UniQure, a clinical stage gene therapy company focused on genetic diseases.Explore more
SwanBio Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SwanBio Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
SwanBio Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on SwanBio Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at SwanBio Therapeutics
Check if SwanBio Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if SwanBio Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if SwanBio Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once SwanBio Therapeutics has new funding data
Product Launch: Get notified when SwanBio Therapeutics launches new products
Recommended Actions
Find VP level buyers at SwanBio Therapeutics
Find more new buyers
Compare Similar Companies to SwanBio Therapeutics
Compare insights from companies similar to SwanBio Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
11-50
Private
$555M
2018
PR
Paul ReinfeldsSenior Vice President - Legal Affairs and General Counsel
Company Profile Activity
Activity Insights
SwanBio Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
SwanBio Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about SwanBio Therapeutics.
SwanBio Therapeutics financials insights
Gather financial insights about SwanBio Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$52M
2022
Series B
$56M
SwanBio Therapeutics Tech Stack
A closer look at the technologies used by SwanBio Therapeutics
See more technologies
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Lateral Move
Executive Move
Board of Directors
Executive Move
Board of Directors
New Hire
Executive Move
Executive Move
Board of Directors
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding SwanBio Therapeutics
Sign Up For FreeTo access detailed company insights
SwanBio Therapeutics, a gene therapy company developing leading-edge medicines to deliver dramatic clinical efficacy for the treatment of adrenomyeloneuropathy (AMN) and other neurological diseases, today announced the appointment of Steven Zelenkofske, D.O., M.S. as chief medical officer (CMO). Dr. Zelenkofske brings more than 20 years of experien... Read More
